Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enzymatica ABFRA:EN9 -5.77%41 EV-to-EBITDA is -11.48 as of Aug. 18, 2026. GuruFocus rates FRA:EN9 with a GF Score™ of 41/100 and a GF Value™ of €0.17 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 734 Drug Manufacturers companies, Enzymatica AB ranks worse than 136239.65% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Enzymatica AB's enterprise value is €44.81 Mil.
Enzymatica AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-3.90 Mil. Therefore, Enzymatica AB's EV-to-EBITDA for today is -11.48.
The historical rank and industry rank for Enzymatica AB's EV-to-EBITDA or its related term are showing as below:
FRA:EN9'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -241.55 Med: -10.65 Max: -3.48
Current: -11.63
During the past 13 years, the highest EV-to-EBITDA of Enzymatica AB was -3.48. The lowest was -241.55. And the median was -10.65.
FRA:EN9's EV-to-EBITDA is ranked worse than 100% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.435
vs FRA:EN9: -11.63
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Enzymatica AB's PE Ratio (TTM) for today is calculated as:
Enzymatica AB's share price for today is €0.147.
Enzymatica AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.019.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Enzymatica AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's EV-to-EBITDA falls into.
Enzymatica AB's current Enterprise Value is €44.81 Mil.
Enzymatica AB's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enzymatica AB (FRA:EN9) has a EV-to-EBITDA of -11.48 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Enzymatica AB. According to the industry distribution chart, Enzymatica AB ranks #999999 out of 734 companies in the Drug Manufacturers industry.
Is Enzymatica AB's EV-to-EBITDA too high?
Enzymatica AB's current EV-to-EBITDA is -11.48. Based on the distribution chart, Enzymatica AB ranks #999999 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enzymatica AB has a GF Score™ of 41/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #999999 out of 734 companies for EV-to-EBITDA. This places Enzymatica AB in the lower half of its industry. The industry median EV-to-EBITDA is 13.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.44, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Enzymatica AB. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current EV-to-EBITDA is -11.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (FRA:EN9) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.17, compared to a current price of €0.15 — trading 13.5% below its estimated fair value. The current EV-to-EBITDA is -11.48. Enzymatica AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Enzymatica AB (FRA:EN9), the current EV-to-EBITDA is -11.48 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (FRA:EN9) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued.
The current stock price of €0.15 is trading 13.5% below its estimated GF Value™ of €0.17.
GuruFocus considers Enzymatica AB to be Modestly Undervalued.
Key valuation signals for FRA:EN9:
EV-to-EBITDA: -11.48
GF Value™: €0.17 vs. price of €0.15 (13.5% below fair value)
No single metric tells the full story. See the FRA:EN9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
41GF Score
Get the complete analysis for FRA:EN9
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EN9 has been successfully added to your 
